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Abstract
Background: Intravesical instillation of bacille Calmette-Guérin (BCG) has been established as efficient therapy for
superficial bladder carcinoma. Overall, intravesical BCG is well tolerated and results in complications of less than
5 %. However, adverse effects such as granulomatous prostatitis, pneumonitis, hepatitis, sepsis, and hypersensitivity
reactions may occur. The reported rate for tuberculous orchitis after BCG intravesical therapy is 0.4 %.
Findings: We report a case of monolateral tuberculous orchitis occurring one month after the second course of
intravescical instillation of bacille Calmette-Guérin in a patient with proven superficial bladder carcinoma and latent
tuberculosis infection.
Conclusions: In our opinion intravesical instillation of BCG should be considered on an individual patient basis,
with full patient disclosure of the potentially significant risks. A screening with an intradermal Mantoux before
starting the first cycle of BCG instillation should be recommended and isoniazid would be indicated as the
treatment for latent tuberculosis infection.
Keywords: Calmette, Guérin, Intravesical, Bladder, Complications
Introduction
Intravesical instillation of bacille Calmette-Guérin
(BCG) has been established as efficient therapy for
superficial bladder carcinoma. Intravesical BCG delays
tumor progression and has been shown to eradicate
residual tumors in 60 % of patients with papillary
carcinoma and in 70 % of patients with carcinoma in
situ [1–4]. Overall, intravesical BCG is well tolerated
and results in complications of less than 5 %. However,
adverse effects such as granulomatous prostatitis, pneu-
monitis, hepatitis, sepsis, and hypersensitivity reactions
may occur [5]. Complications can appear early (within
3 months after instillation) or years after the first BCG
treatment. Early-presentation disease is characterized by
generalized symptoms, pneumonitis and hepatitis. Late-
presentation disease is usually localized, with no systemic
manifestations and the infection involves often the
genitourinary tract and/or other sites that are typical
for reactivation of mycobacterial disease, such as the
vertebral spine or the retroperitoneal tissues. The reported
rate for tuberculous orchitis after BCG intravesical therapy
is 0.4 % [5]. We report a case of monolateral tuberculous
orchitis occurring one month after the second course of
intravesical instillation of BCG in a patient with proven
superficial bladder carcinoma and latent tuberculosis
infection.
Case report
A 69-year-old patient came to Infectious Disease Unit of
the “P. Giaccone” Teaching Hospital in Palermo, Italy,
because of painful and progressive monolateral scrotal
swelling. Two years earlier the patient underwent
transurethral resection of a papillary carcinoma of the
bladder, followed, after about two weeks from surgery, by
a course of intravesical BCG therapy (six instillations
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weekly). The following year, during cystoscopy follow-up,
a second course of BCG intravesical therapy was required
due to a doubtful recurrence. After about six weeks from
the end of the second therapy course, control cystoscopy
and irrigation cytology were performed and showed no
evidence of bladder carcinoma and normal urine cytology
(Papanicolaou II). Nevertheless, maintenance dose of
intravesical BCG therapy (one instillation every three
weeks for about one-three years) was made and one
month after the last instillation the patient began to com-
plain of scrotal swelling. The patient had a medical history
of type 2 diabetes and ulcerative rectocolitis on treatment
with metformin and mesalazine respectively. On admis-
sion, the temperature was 36.9 °C, the blood pressure 130/
70 mmHg, the pulse 100 beats per minute, the respiratory
rate 18 breaths per minute and the oxygen saturation
96 % while he was breathing ambient air. The urine cul-
ture was negative. The left testis contained a soft painful
mass with a cutaneous fistula; an ultrasound scan showed
the presence of an abscess and surgery was required. Left
orchiectomy and funiculus spermaticus ligature were
performed, specimens were sent for histopathology and
microbiological tests (bacterial culture). Histological
investigation on testis showed a chronic granulomatous
disease presenting with giant cells Langhans type, caseous
necrosis and purulent abscess overlap. A computed
tomography of the chest showed bilateral apical fibro-
sis and the presence of millimeter nodules in the
right pulmonary lobe. An Interferon-Gamma Release
Assay (QuantiFERON-TB Gold, Cellestis, Ltd., Carnegie,
Australia) was performed and immune reactivity to
Mycobacterium tuberculosis (Mtb) was proved whereas
three sputum and urine sample examination with the
Ziehl Neelsen (ZN) technique and Polymerase Chain
Reaction (PCR) for Mycobacterium tuberculosis were
negative. Because of the BCG instillations therapy history,
treatment with rifampicin 600 mg daily, isoniazid 300 mg
daily and ethambutol 1500 mg daily was started. There-
fore patient was discharged with indication to continue
antituberculosis therapy for six month of isoniazid plus
rifampicin with a two month of intensive phase including
ethambutol.
Discussion
The intravesical administration of BCG has become a
mainstay of adjunctive therapy for superficial bladder
cancer. Although usually well tolerated, both local and
systemic BCG-related complications may occur follow-
ing instillation. These events are uncommon (<5 %) and
the majority of patients tolerate BCG therapy without
significant morbidity [1–6]. The mechanism of action of
BCG in bladder cancer is still unclear and probably is
specific anti-BCG cell-mediated immunity. BCG triggers
a variety of local immune responses that appear to
correlate with antitumor activity. Studies of the im-
munological mechanism of BCG therapy show that an
intact immune system, particularly the cellular system, is
required for antitumor activity because mycobacterial
antigen presentation by phagocytes to T helper cells is
the pivotal interaction [7]. The pathogenic mechanisms
underlying the development of complications following
BCG instillation remain not fully understood. Most of
the symptoms associated with BCG immunotherapy are
the result of the immune stimulation that is required to
effectively eradicate cancer cells or are an ongoing active
infection. These symptoms include urinary frequency
and burning, mild malaise, and low-grade fever. Dissem-
inated infection is the most common manifestation. This
complication consist of miliary tuberculosis, fever
associated to bone marrow and/or liver infiltration,
sepsis with multiorgan failure, or persistent fever as the
unique clinical manifestation responding to antitubercu-
losis treatment [8–10]. Localized and late infection can
involve osteoarticular apparatus (spondylodiscitis),
muscles, vessels (aneurysms and pseudoaneurysms), eyes
(granulomatous anterior uveitis, endophthalmitis, auto-
immune retinopathy) and genitourinary tract (cystitis
and sterile pyuria, diffuse prostatic enlargement or
focal nodule or abscess, nephritis, epididymo-orchitis)
[5, 10, 11]. Our patient developed epididymo-orchitis
without generalized symptoms one month after the
second course of six weekly intravesical instillation of
BCG. It is known that diabetic patients have a greater
risk of developing tuberculosis and that poor glycemic
control is associated with complications from intravesical
BCG [12]. However, our patient has a well-compensated
diabetes. The patient did not report history of tuberculosis
but a computed tomography scan showed nodular lesions
in the right pulmonary lobe and he had a positive
QuantiFERON-TB Gold test. Its positivity only indicates
previous contact with Mycobacterium tuberculosis and it
is not useful for the diagnosis of BCG complications.
Several studies demonstrated that the antitumor effect of
BCG is not immediate but is the consequence of prior
immune stimulation and for this reason some patients do
not respond to an initial 6-week course of BCG and need
an additional 6-week course of BCG to become tumor-
free [13]. A previous tuberculosis or a latent tuberculosis
infection do not seem to be associated with a higher risk
of BCG complications. Other authors found no significant
differences in terms of previous diagnosis of active or
latent tuberculosis infection between patients with and
without systemic BCG infection. Mucosal disruption of
the urogenital epithelium caused by difficult bladder cath-
eterizations, preexisting cystitis or persistent hematuria
following transurethral resection of the bladder tumor, is
the main predisposing factor [10]. Concurrent prophylac-
tic use of isoniazid with intravesical instillation has largely
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been unsuccessful in the protection against BCG
complication. On the contrary prophylactic use of
ofloxacin may be more effective [14, 15]. A screening
with an intradermal Mantoux before starting the first
cycle of BCG instillation should be recommended.
Active tuberculosis has to be ruled out and isoniazid
would be indicated as the treatment for latent tuber-
culosis infection. Patient monitoring is important for
the diagnosis and early treatment of BCG therapy
related complications.
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